MapleTech Publishes New Website
HOLMDEL, N.J., May 13, 2025 (GLOBE NEWSWIRE) — Maple Technologies (MapleTech), developer of the Aspire suite, a platform of integrated modules for processing personal and commercial Property & Casualty insurance, published a new website as part of the re- positioning of its brand. The new site features improved navigation; more descriptive content of Aspire's flexibility and capabilities; a new, interactive blog called, Samaras ; and easier access to contact information.
'We've evolved steadily since our founding in 2001,' said Matt Blackley, President and CEO of MapleTech. 'Given the ways in which we've evolved, Aspire has evolved, and technology continues to evolve, it made good business sense to let that evolution be reflected in a commensurate evolution of our website. Samaras are the seeds from maple trees, sometimes called helicopters or whirlybirds, that spin and disseminate from the parent tree, sometimes 300 feet or more, before taking root. We call our blog Samaras , because our posts are the seeds with which we disseminate our knowledge, letting it take root with our readers.'
Aspire is a web-facing, configurable, scalable, and secure core processing system for Property & Casualty insurance. It provides all the requisite policy, billing, and claims functionality to enable insurers to improve profitability and manage risk effectively. It allows insurers to respond to market changes, client needs, and regulatory updates easily and efficiently. And MapleTech's private cloud ensures near 100 percent uptime with guaranteed scalability, data redundancy, authentication standards, and user-determined authorization levels.
About MapleTech
Maple Technologies is the developer of Aspire, a core processing system for Property & Casualty insurance. Aspire is used by carriers, reciprocals, risk-retention groups, captives, self-insureds, and MGAs that write personal, commercial, and specialty lines. Aspire is flexible, configurable, and reliable. Available as a pre-integrated suite or as standalone components, Aspire integrates with other systems and data sources with flexible APIs. It features configurable workflows. And by streamlining operations and enhancing efficiency, Aspire helps insurers reduce costs and improve profitability. For more details please visit www.maple-tech.com/, call (732) 863-5523, or email [email protected] .
Media contact:JoAnna BennettO'Brien Communications Group(201) 341-2360
[email protected]
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Black Hills Corp. Receives Approval For 99 MW Dispatchable Generation Resource in South Dakota
RAPID CITY, S.D., June 11, 2025 (GLOBE NEWSWIRE) -- Black Hills Corp. (NYSE: BKH) today announced that its South Dakota electric utility subsidiary serving South Dakota and eastern Wyoming has received approval from the Wyoming Public Service Commission for a certificate of public convenience and necessity (CPCN) that supports the need for its Lange II Project, a 99 MW dispatchable generation resource in Rapid City, South Dakota. The approval allows commencement of construction of the project, which addresses a capacity deficit resulting from the retirement of other aging generation units, as well as an increase in planning reserve margin to ensure the utility has a reliable energy supply. Lange II will include six reciprocating internal combustion engines (RICE) with dual-fuel optionality of natural gas and diesel, and related interconnection facilities. These were identified as the least-cost resource to continue to reliably serve customers in South Dakota and eastern Wyoming. The project is estimated to cost $280 million. 'We are committed to providing our customers with the safe, reliable and cost-effective electric service they depend on,' said Linn Evans, president and CEO of Black Hills Corp. 'Notably, these RICE units will enhance resiliency of the electric system and the ability to quickly respond to fluctuations in demand needs for our customers.' Construction is planned to commence during the third quarter of 2025 and the project is expected to start serving customers in the second half of 2026. Black Hills CorporationBlack Hills Corp. (NYSE: BKH) is a customer-focused, growth-oriented utility company with a tradition of improving life with energy and a vision to be the energy partner of choice. Based in Rapid City, South Dakota, the company serves 1.35 million natural gas and electric utility customers in eight states: Arkansas, Colorado, Iowa, Kansas, Montana, Nebraska, South Dakota and Wyoming. More information is available at Investor RelationsSal Diaz605-399-5079Investorrelations@ 24-Hour Media Relations Line888-242-3969Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
31 minutes ago
- Associated Press
Conavi Medical to Present at the Life Sciences Virtual Investor Forum June 12th
TORONTO, June 11, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) ('Conavi Medical' or the 'Company'), a commercial-stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, today announced that Thomas Looby, CEO, will present live at the Life Sciences Virtual Investor Forum hosted by on June 12th, 2025 DATE: June 12th TIME: 2:00 PM ET LINK: REGISTER HERE This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event. It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates. Learn more about the event at . Recent Company Highlights Upsized $20 million CAD financing led by U.S. institutional investors is expected to support finalizing product development of the next-generation Novasight Hybrid system, submit for regulatory clearance and enable commercial launch New U.S. intracoronary imaging guidelines from the American College of Cardiology and recent peer-reviewed research strongly validate Novasight's unique value proposition U.S. FDA 510(k) submission remains on track for calendar Q3 2025 About Conavi Medical Conavi Medical is focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented Novasight Hybrid™ System is the first system to combine both intravascular ultrasound (IVUS) and optical coherence tomography (OCT) to enable simultaneous and co-registered imaging of coronary arteries. The Novasight Hybrid System has 510(k) clearance from the U.S. Food and Drug Administration; and regulatory approval for clinical use from Health Canada, China's National Medical Products Administration, and Japan's Ministry of Health, Labor and Welfare. For more information, visit . About Virtual Investor Conferences® Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors. Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors. Forward-Looking Statements This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding Conavi and its business, which may include, but are not limited to, statements with respect to the anticipated use of proceeds from the April 2025 public offering, Conavi's exposure to the U.S. investment community, the commercialization and development of the Novasight Hybrid System and the achievement and timeline of key milestones towards commercialization and development of the Novasight Hybrid System. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are 'forward-looking information or statements'. Often but not always, forward-looking information or statements can be identified by the use of words such as 'shall', 'intends', 'anticipate', 'believe', 'plan', 'expect', 'intend', 'estimate' 'anticipate' or any variations (including negative variations) of such words and phrases, or state that certain actions, events or results 'may', 'might', 'can', 'could', 'would' or 'will' be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. They are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, those listed in the 'Risk Factors' section of the short form prospectus dated April 15, 2025 and the joint information circular of the Company dated August 30, 2024 (both of which are on the Company's profile at ). Although Conavi has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Conavi does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. No regulatory authority has approved or disapproved the content of this press release. Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release. Contacts: Conavi Medical Stefano Picone Chief Financial Officer [email protected] (416) 483-0100 Virtual Investor Conferences John M. Viglotti SVP Corporate Services, Investor Access OTC Markets Group (212) 220-2221 [email protected]
Yahoo
36 minutes ago
- Yahoo
Conavi Medical to Present at the Life Sciences Virtual Investor Forum June 12th
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at TORONTO, June 11, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) ('Conavi Medical' or the 'Company'), a commercial-stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, today announced that Thomas Looby, CEO, will present live at the Life Sciences Virtual Investor Forum hosted by on June 12th, 2025 DATE: June 12th TIME: 2:00 PM ETLINK: REGISTER HERE This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event. It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates. Learn more about the event at Recent Company Highlights Upsized $20 million CAD financing led by U.S. institutional investors is expected to support finalizing product development of the next-generation Novasight Hybrid system, submit for regulatory clearance and enable commercial launch New U.S. intracoronary imaging guidelines from the American College of Cardiology and recent peer-reviewed research strongly validate Novasight's unique value proposition U.S. FDA 510(k) submission remains on track for calendar Q3 2025 About Conavi MedicalConavi Medical is focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented Novasight Hybrid™ System is the first system to combine both intravascular ultrasound (IVUS) and optical coherence tomography (OCT) to enable simultaneous and co-registered imaging of coronary arteries. The Novasight Hybrid System has 510(k) clearance from the U.S. Food and Drug Administration; and regulatory approval for clinical use from Health Canada, China's National Medical Products Administration, and Japan's Ministry of Health, Labor and Welfare. For more information, visit About Virtual Investor Conferences®Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors. Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors. Forward-Looking StatementsThis press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding Conavi and its business, which may include, but are not limited to, statements with respect to the anticipated use of proceeds from the April 2025 public offering, Conavi's exposure to the U.S. investment community, the commercialization and development of the Novasight Hybrid System and the achievement and timeline of key milestones towards commercialization and development of the Novasight Hybrid System. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are "forward-looking information or statements". Often but not always, forward-looking information or statements can be identified by the use of words such as "shall", "intends", "anticipate", "believe", "plan", "expect", "intend", "estimate" "anticipate" or any variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "might", "can", "could", "would" or "will" be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. They are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, those listed in the "Risk Factors" section of the short form prospectus dated April 15, 2025 and the joint information circular of the Company dated August 30, 2024 (both of which are on the Company's profile at ). Although Conavi has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Conavi does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or regulatory authority has approved or disapproved the content of this press the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release. Contacts: Conavi MedicalStefano PiconeChief Financial Officerir@ 483-0100 Virtual Investor Conferences John M. ViglottiSVP Corporate Services, Investor AccessOTC Markets Group (212) 220-2221johnv@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
